Patents Examined by D. Bernstein
-
Patent number: 5098703Abstract: A new polypeptide, called IFN-.alpha.76, produced by E. coli transformed with a newly isolated and characterized human IFN-.alpha. gene is described. The polypeptide exhibits interferon activities such as antiviral activity, cell growth regulation, and regulation of production of cell-produced substances.Type: GrantFiled: September 2, 1982Date of Patent: March 24, 1992Assignee: Cetus CorporationInventor: Michael A. Innis
-
Patent number: 5047508Abstract: A monoclonal antibody MHS-5 which specifically binds to a seminal vesicle specific antigen, SVSA, wherein the seminal vesicle specific antigen is secreted by the principal cells of the seminal vesicle epithelium. The method for producing this monoclonal antibody is also disclosed.Type: GrantFiled: April 21, 1987Date of Patent: September 10, 1991Assignee: The University of Virginia Alumni Patents FoundationInventors: John C. Herr, Mark Sigman, William M. Sutherland
-
Patent number: 5028424Abstract: The present invention encompasses a receptor molecule present on the surface of natural killer cells (NK cells) and non-specific cytotoxic cells (NCC) which is involved in non-specific lysis of target cells bearing an antigen recognized by the receptor molecule, an antigen common to the surface of cells recognized and lysed by natural killer cells, monoclonal and heterologous antibodies which bind to the receptor and target cell antigen(s) which are useful in their identification and purification, and methods for altering NK cell-mediated lysis of target cells.The monoclonal antibodies (mAbs) of the present invention were prepared by cell fusions between spleen cells from mice immunized with either non-specific cytotoxic cells (NCC) from catfish (anti-receptor antibodies) or NC-37 human lymphoblastoid B-cells, which are susceptible to lysis by NK cells, and myeloma cells. Eight distinct mAbs have been characterized, four directed against the NK/NCC target cell receptor and four against the NK/NC cell antigen.Type: GrantFiled: October 16, 1987Date of Patent: July 2, 1991Assignee: University of Georgia Research FoundationInventor: Donald L. Evans
-
Patent number: 5019513Abstract: A method of protecting a mammal against a pathogenic bacterium by administering a soluble suppressor T-cell factor derived from a mammal that has been immunized with the bacterium or an antigenic surface fragment of the bacterium. Also disclosed are a hybrid cell fusion of an immunized suppressor T cell, methods of making such cells, and method of producing soluble suppressor T-cell factors.Type: GrantFiled: January 12, 1989Date of Patent: May 28, 1991Assignee: The Brigham and Women's Hospital, Inc.Inventors: Dennis L. Kasper, Dori F. Zaleznik, Robert W. Finberg
-
Patent number: 5017687Abstract: Four peptides corresponding to regions of the glycoprotein encoded by the env gene of HTLV1 are provided. These peptides which are immunologically reactive with HTLV-1 specific antibodies are useful in assays for detection of HTLV-1 infection or exposure and in compositions to elicit the production of antibodies against HTLV-1 in animals and man.Type: GrantFiled: June 13, 1988Date of Patent: May 21, 1991Assignee: Virovahl, S.A.Inventors: Anders Vahlne, Bo Svennerholm, Lars Rymo, Stig Jeansson, Peter Horal
-
Patent number: 5002870Abstract: A method and reagents are provided for determining whether a human cell is a hemopoietic cell and whether a human tissue cell is in a neoplastic state. Human cells which express only leukocyte-plastin (1-plastin) are hemopoietic cells and human cells which express both 1-plastin and tissue-plastin (t-plastin) are neoplastic. The method can be performed using isoform-specific plastin nucleotide probes or isoform-specific antiplastin antibodies.Type: GrantFiled: March 16, 1990Date of Patent: March 26, 1991Assignee: California Institute for Medical ResearchInventors: John C. Leavitt, Ching-Shwun Lin, Ruedi H. Aebersold
-
Patent number: 4975276Abstract: A new polypeptide, called IFN-.alpha.54, produced by E. coli transformed with a newly isolated and characterized human IFN-.alpha. gene is described. The polypeptide exhibits interferon activities such as antiviral activity, cell growth regulation, and regulation of production of cell-produced substances.Type: GrantFiled: September 2, 1982Date of Patent: December 4, 1990Assignee: Cetus CorporationInventor: Michael A. Innis
-
Patent number: 4973479Abstract: A new polypeptide, called IFN-.alpha.61, produced by E. coli transformed with a newly isolated and characterized human IFN-.alpha. gene is described. The polypeptide exhibits interferon activities such as antiviral activity, cell growth regulation, and regulation of production of cell-produced substances.Type: GrantFiled: September 2, 1982Date of Patent: November 27, 1990Assignee: Cetus CorporationInventor: Michael A. Innis